PDA

View Full Version : Mexican Flu Outbreak 2009 - Dr Leonard Horowitz


kanuck57
05-04-2009, 08:23 PM
Watch GoogleVideo - Mexican Flu Outbreak 2009: SPECIAL REPORT by Dr Leonard Horowitz 11 mins:
http://www.youtube.com/watch?v=GBeKB7aKzOs


H1N1-H5N1 Flu Outbreak Implicates Anglo-American “Vaccine Pipeline” Says Expert Dr. Leonard Horowitz
http://www.drlenhorowitz.com/Press/press_releases/novavaxcdc_specialreport.htm

Los Angeles, CA— Skyrocketing stock values of Novavax, Inc.,(1) precipitated by dozens of flu deaths in Mexico, implicates a leading Anglo-American network of genetic engineers in a conspiracy to commit genocide, according to a Harvard trained expert in emerging diseases, Dr. Leonard Horowitz.

Dr. James S. Robertson, England’s leading bioengineer of flu viruses for the vaccine industry, and avid promoter of U.S. Government funding for lucrative “biodefense” contracts, along with collaborators at the US Centers for Disease Control & Prevention (CDC), helped Novavax, Inc., in Bethesda, Maryland, produce genetically-modified recombinants of the avian, swine, and Spanish flu viruses, H5N1 and H1N1, nearly identical to the unprecedented Mexican virus that has now spread to the United States. The outbreak was precisely timed to promote the company’s new research and huge vaccine stockpiling contracts, according to Dr. Horowitz.(2)

Scientists at the U.S. Centers for Disease Control (CDC) are implicated through collaborations and publications involving private contracts with Novavax, a company that obtains its “biosimulars” through CDC Influenza Branch director, Ruben O. Donis, and Dr. Rick Bright, previously working with Donis at the CDC, now Novavax’s Vice President of Global Influenza Programs.

Evidence for the conspiracy to commit deadly duplicity in the vaccine industry includes the genetic markers on the novel flu virus now spreading from Mexico to America. The virus is “genetically different from the fully human H1N1 seasonal influenza virus that has been circulating globally for the past few years,” according to Reuters and government officials. “The new flu virus contains DNA typical to avian, swine and human viruses, including elements from European and Asian swine viruses.”(3)

“That is a description that is pathognomonic, or diagnostic, of a virus that came from Robertson’s circle of friends,” Dr. Horowitz claims. “No other group in the world takes H5N1 Asian flu infected chickens, brings them to Europe, extracts their DNA, combines their proteins with H1N1 viruses from the 1918 Spanish flu isolate, additionally mixes in swine flu genes from pigs, then ‘reverse engineers’ them to infect humans. The end product that Reuter’s describes could only end up in Mexico via the United States from Britain in care of the CDC. Ruben Donis at the CDC had to have sent them to Novavax, where Rick Bright’s team is now implicated in a conspiracy to commit genocide—the mass killing of people for profit.”

Novavax’s preliminary report in the Journal of Virology, with co-authors from the CDC in Atlanta, was posted online at the precise time Mexican officials began reporting deaths from this new strain of flu that is clearly an unprecedented recombinant of at least three H1N5 and H1N1 strains. Novavax’s Johnny-on-the-spot vaccine was prepared under the CDC’s “fast track” approval process speciously using these three strains never known to infect any human in Mexico.

Therefore, the statistical probability this virus came from this company of “experts” is extremely high. Alternatively, anticipated arguments the virus arrived in Mexico by serendipity, at this precise time in Novavax’s history, is ridiculously remote.

“These doctor’s conflicting corporate, scientific, and financial interests evidence criminal malfeasance,” said Dr. Leonard Horowitz, an internationally known humanitarian, award winning consumer health activist, and author of sixteen books.

“The most chilling evidence against the Robertson-Novavax (RN) vaccine pipeline, besides Robertson being the “gatekeeper” for multi-billion dollar vaccine stockpiling deals, is Robertson’s influence over the European Medicines Agency (EMEA)—a quasi-corporate quasi-scientific think tank serving the European [Economic] Union and drug industry’s special interests,” Dr. Horowitz said.

Dr. Robertson is the Principal Scientist in the Division of Virology at the National Institute for Biological Standards and Control (NIBSC), akin to the USFDA in the UK. During a meeting in April, 2006, discussing the standardization of influenza vaccines on behalf of the World Health Organization (WHO), it was disclosed, “the NIBSC is involved in the serological testing of vaccine trials; the preparation and distribution of influenza viruses to vaccine manufacturers; and the coordination of EU strain selection[s].” Participants disclosed the EMEA persuades vaccine makers to bank on pandemics, and “invest in pandemic vaccines with the introduction of mock up files,” which is their unassuming way of describing new laboratory engineered influenza viruses also referred to as “biosimilars.” (4)

The EMEA waves regulatory fees as an additional incentive to attract more business for allegedly “biodefense.”(4)

Dr. Robertson, the holder of intellectual property (IP) rights to the genetic technology used to produce the H5N1 and H1N1 “mock up files” used to develop Novavax’s vaccine, waived his ownership of the technology during the company’s research phase with a guaranteed payoff “when the vaccine is commercialized.” Robertson’s “Material Trade Agreement” (MTA), covering the transfer of these “biosimilars” to Novavax, is expected to return millions of dollars when the vaccine is sold to governments worldwide. (4)

Novavax’s commercialization and promotions of their vaccine is largely based on media hype fanning fears and markets for their avian flu, Spanish flu, and swine flu concoctions. Never before this outbreak has such a virus, combining the three most feared flu strains, been identified.

Mexico’s killer, therefore, evidences a laboratory creation sourcing from either Novavax’s lab directly, or their partners at the CDC and NIBSC who maintain multi-million-dollar incentives. The company’s synchronously timed professional publications, mass media releases, product representations and commercialization, evidence financial motives to commit duplicity and mass murder.

Days ago, officials at the CDC expressed serious concerns about this novel flu strain causing a deadly pandemic, not disclosing their obvious knowledge that the outbreak must have sourced from the materials used in their cooperative studies with Novavax.(5)

“These doctor’s conflicting corporate, scientific, and financial interests evidence criminal malfeasance. Killing dozens of people for publicity and duplicity in public health; to increase marketability of their new vaccine, is best described as serial homicide to advance genocide—the mass killing of people for profit,” Dr. Leonard Horowitz explained.

The most chilling evidence against Dr. Robertson’s EU research team, besides him being the gatekeeper and chief promoter for multi-billion dollar flu vaccine stockpiling deals, and besides his collaborators being caught red handed here by hard science and common sense, is his stated position that he believes it is wise to “prime” populations worldwide by releasing viruses he and his colleagues are creating.

This warning comes from a April 27, 2006, scientific discourse in which Dr. Robertson, and members of his WHO working group, recommended his “biosimilars” be “used to prime the population in advance of the pandemic reaching the UK.” (http://royalsociety.org/downloaddoc.asp?id=3526)

In other words, the doctors that hold infectious disease responsibility for the world have already decided to loose their viruses on unwitting populations in advance of threatened outbreaks.

-End-



References links repaired:

(1)http://uk.reuters.com/article/governmentFilingsNews/idUKN2445216420090424

(2) http://ukpmc.ac.uk/articlerender.cgi?artid=1242433

(3) Reuters news release. FACTBOX-New flu strain is a genetic mix. April,24,2009. http://www.alertnet.org/thenews/newsdesk/N23371192.htm

(4) PDF - http://royalsociety.org/downloaddoc.asp?id=3521

HTML http://74.125.95.132/search?q=cache:SPJ1B5-EK3sJ:royalsociety.org/downloaddoc.asp%3Fid%3D3521+Summary+of+Oral+Eviden ce
+Dr.+John+Wood&cd=1&hl=en&ct=clnk&gl=us&client=firefox-a

(5) “CDC Press Briefing Transcripts April 24, 2009”. Cdc.gov. 2009-04-24. http://www.cdc.gov/media/transcripts/2009/t090424.htm. Retrieved on 2009-04-25.



.

Mama Alanna
05-04-2009, 09:53 PM
:re: :tin:

Sysiphus
05-04-2009, 09:58 PM
So, of course, references (1) and (2) are dead links. Time to bring back the Super Flu Super Speculation folder, if you ask me. A special folder for really outlandish stuff like this.

CanadaSue
05-04-2009, 11:20 PM
The Flu Spec page IS for outlandish stuff.

And Horowitz is as outlandish as they come.

kanuck57
05-05-2009, 08:28 PM
Summary of oral evidence: Dr John Wood and Dr James
Robertson, National Institute for Biological Standards and
Control (NIBSC)
27 April 2006
http://royalsociety.org/downloaddoc.asp?id=3526

Use of live vaccines

Drs Wood and Robertson were asked their opinion on priming the population for a pandemic using live vaccines and if they consider it to be a good idea. However the timing is critical; if live H5N1 vaccines are used now it would be considered too dangerous, but if a pandemic is imminent the risk may be justified. A stockpile of live vaccine, with the cleavage site removed, could be used to prime the population in advance of the pandemic reaching the UK. Even without an exact match in virus strain, it is predicted that this would
provide a broad immunity to the population.

kanuck57
05-10-2009, 06:42 PM
Reference - 1


Venture capital firm set to reap rewards on swine flu
Fri Apr 24, 2009 11:11pm BST

http://uk.reuters.com/article/governmentFilingsNews/idUKN2445216420090424?pageNumber=1&virtualBrandChannel=0

By Alexander Haislip

LOS ANGELES, April 24 (Reuters) - The swine flu outbreak is likely to benefit one of the most prolific and successful venture capital firms in the United States: Kleiner Perkins Caufield & Byers, Thomson Reuters Private Equity Week reported on Friday.

Shares of the two public companies in the firm's portfolio of eight Pandemic and Bio Defense companies -- BioCryst Pharmaceuticals (BCRX.O) and Novavax (NVAX.O) -- jumped Friday on news that the swine flu killed a reported 60 people in Mexico and has infected people in the United States.

The World Health Organization said the virus appears to be susceptible to Roche's (ROG.VX) flu drug Tamiflu, also known as oseltamivir, but not to older flu drugs such as amantadine.

Shares of Swiss drugmaker Roche Holding AG closed up 3.48 percent after falling sharply earlier in the week on a cancer drug disappointment, while shares of U.S. biotechnology company Gilead Sciences Inc (GILD.O), which gets royalties from Roche on Tamiflu sales, slipped 10 cents to $45.80 on Friday.

But BioCryst, a maker of drugs that block key enzymes in viral diseases, jumped more than 26 percent on Friday to $2.21 per share. Viral vaccine maker Novavax rose more than 75 percent to $1.42 per share.

BioCryst CEO John Stonehouse said his company does not anticipate the use of its technology in treating this episode of swine flu.

"We're in clinical trials right now and not on the market," Stonehouse said.

Still, the companies will have to go even higher for Kleiner Perkins to make its investment back. Both BioCryst and Novavax experienced long drops from price peaks in 2006, when reports of avian flu dominated headlines.

BioCryst is down nearly 90 percent from its 2006 high of $20.75 per share and Novavax is down more than 85 percent from a high of $7.98 per share.

Kleiner Perkins invested $30 million in BioCryst in December 2005 alongside Fort Worth, Texas-based buyout firm TPG. The two firms invested again in August 2007, picking up $65 million worth of shares and warrants. The investors bought shares in BioCryst at $13.46 and then $7.80.

Kleiner Perkins put $20 million in Novavax in February 2006 alongside Palo Alto, Calif.-based Prospect Venture Partners. The two firms picked up the shares at $4.35.

Novavax can produce a vaccine from an emergent strain of flu virus in 12 weeks, according to CEO Rahul Singhvi. The company has contacted the U.S. Centers for Disease Control and Prevention to offer help and is trying to contact the Ministry of Health in Mexico, Singhvi said.

The company uses genetic information and "recombinant, virus-like particle technology" to rapidly engineer a vaccine. Its technology has been proven to work in humans during Phase II trials, Singhvi said, and it might be used in the case of an emergency.

"There is an emergency authorization avenue that is available that would allow us to use the vaccine in an emergency without further testing," said Singhvi.

Kleiner Perkins typically only invests in early stage start-up technologies. It is best known for its investments in Netscape, Amazon.com (AMZN.O), Google (GOOG.O) and Genentech (ROG.VX).

The Menlo Park, California-based VC firm launched a $200 million Pandemic Bio Defense fund in 2006 to invest in technology companies working on drugs, diagnostics and inoculations against flu-like diseases.

"We will invest to accelerate innovation, and we're in a hurry," Investor John Doerr said at the time. "We hope even a mild pandemic never recurs."

Investors at Kleiner Perkins were not immediately available for comment.

The firm's other Pandemic Bio Defense investments include: * San Francisco-based Anza Therapeutics, which is working on therapeutic vaccines for treating certain types of cancer and hepatitis C. * Fremont, Calif.-based Breathe Technologies, which is working on lightweight respiratory ventilator systems. * Emeryville, Calif.-based HX Diagnostics, which is working to make diagnostic tools for seasonal and emerging diseases. * Pleasanton, Calif.-based Juvaris BioTherapeutics Inc., which is working on vaccines and immunotherapeutics to treat infectious disease and cancer. * San Diego-based Trius Therapeutics, which is developing drugs to fight resistant-strains of bacteria. * Marlborough, Mass.-based Xcellerex Inc., which has developed tools and manufacturing processes to speed the deployment of new vaccines.



.